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Abstract
Podocytes are injured in several glomerular diseases. To alter gene expression specifically in podocytes in vivo, we took
advantage of their active endocytotic machinery and developed a method for the targeted delivery of small interfering
ribonucleic acids (siRNA). We generated an anti-mouse podocyte antibody that binds to rat and mouse podocytes in vivo.
The polyclonal IgG antibody was cleaved into monovalent fragments, while preserving the antigen recognition sites. One
Neutravidin molecule was linked to each monovalent IgG via the available sulfohydryl group. Protamine, a polycationic
nuclear protein and universal adaptor for anionic siRNA, was linked to the neutravidin via biotin. The delivery system was
named shamporter (sheep anti mouse podocyte transporter). Injection of shamporter coupled with either nephrin siRNA or
TRPC6 siRNA via tail vein into normal rats substantially reduced the protein levels of nephrin or TRPC6 respectively,
measured by western blot analysis and immunostaining. The effect was target specific because other podocyte-specific
genes remained unchanged. Shamporter + nephrin siRNA induced transient proteinuria in rats. Control rats injected with
shamporter coupled to control-siRNA showed no changes. These results show for the first time that siRNA can be delivered
efficiently and specifically to podocytes in vivo using an antibody-delivery system.
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Introduction
Podocytesarehighlyspecializedterminallydifferentiatedepithelial
cells.Togetherwiththeglomerularbasementmembrane(GBM)and
endothelialcells,theycomprisetheglomerularfiltrationbarrierofthe
kidney. Podocytes are injured ina variety of acquired and congenital
diseases by immune and non-immune mediated mechanisms [1,2].
Although genetic approaches have made enormous contributions to
our understanding of podocyte disease, the generation of animals by
specific gene engineering are typically limited to mice [3], although
several groups have recently reported on gene manipulation in rats
[4]. The genetic approach however, is time consuming and costly,
and cannot be performed in man. Moreover, in contrast to several
well defined and characterized experimental podocyte disease
models in rats such as the passive Heymann nephritis, puromycin
nephrosis, the remnant kidney model and others [5], the number of
mouse models available to study podocyte diseases are limited in
number, and are also substantially less well defined.
Thus, from an investigational and potentially therapeutic
standpoint, the ability to modify genes in established podocyte
disease models as well as to have the ability to alter expression in
man is desirable.
In order to address this goal, we employed the use of RNA
interference (RNAi) [6,7]. RNAi has advantages in that it can
reduce the expression of genes that are either constitutively
expressed in cells, or genes that are increased following a stimulus
such as injury. The commonly used methods used to transfer
RNAi molecules into cells in culture include electroporation, lipid-
based transfection reagents or nanoparticles. Unfortunately, when
employed in vivo, these methodologies are not cell specific, thus
limiting their utility in vivo for delivering RNAi to target specific
organs or specific cell types within that organ. Recent evidence has
emerged that podocytes have a robust machinery for endocytosis
[8], which may be statin dependent [9]. It has also been shown
that podocytes utilize an IgG and albumin transport mechanism to
remove IgG from the glomerular basement membrane (GBM)
[10]. In this study, we took advantage of podocyte endocytosis to
devise a novel method for podocyte specific uptake of siRNA in
vivo, allowing specific modulation of gene expression.
Results
Construction of the Delivery Antibody
Central to this technique is an anti mouse podocyte antibody
generated in sheep. The antibody was modified so that (i) it could
be used as a vehicle to deliver small nucleic acids (siRNA) to
podocytes in vivo and (ii) to minimize stimulation of the host
immune system, such as complement activation. Modification and
the hypothetical mode of action of the antibody is shown in
Figure 1 and described in the method section.
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9463Figure 1. Design of Shamporter (sheep anti mouse podocyte & transporter). Shamporter is a modified anti podocyte antibody that
piggybacks siRNA to a target cell. (A) Specific cleaving of the anti mouse podocyte divalent IgG at the inter-heavy chain disulfide bond, using 2-
Mercaptoethylamine, results in monovalent IgG. (B) A Neutravidin binding site is conjugated to the available sulfohydryl group. (C) Protamine is
biotinylated which then binds to the monovalent IgG. (D and E) Negatively charged siRNA molecules bind to the positively charged protamine
domain of the shamporter construct. (F) The modified antibody (shamporter) carrying siRNA binds to the podocytes. The bound antibody is
internalized and transported to the cytoplasm. Uncoating of the endosomatic vesicle releases the transported siRNA into the cytoplasm. The released
siRNA activates RISC (RNA induced silencing complex), which is followed by degradation of the target mRNA.
doi:10.1371/journal.pone.0009463.g001
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Immunogold staining of normal mouse kidneys was performed
to determine the cellular affinity of the antibody generated for
these studies. Our results revealed the presence of immunogold
particles in the glomerulus, predominantly in podocytes
(Figure 2.A). A very small number of immunogold particles also
bound endothelial cells in mouse glomeruli (Figure 2.A). These
results show that the antibody used in these studies bound
predominantly to antigen(s) on podocytes. To test for potential
uptake of the podocyte antibody by the proximal tubular cells,
antibody was injected into rats. Immunofluorescent staining for
sheep anti podocyte IgG was detected only in the glomerulus
(Figure 2.B). No staining was observed in the tubulointerstitial
region, consistent with the notion that uptake of the antibody by
tubular cells was absent, and is thus glomerular limited
(Figure 2.D).
Anti-Podocyte Antibody Localizes to Podocyte
Membranes
To validate that the anti-podocyte antibody indeed binds to the
cell membrane of podocytes and not other glomerular cells,
membrane fractions of cultured immortalized mouse podocytes
(P), mouse mesangial cells (MC) [11], mouse fibroblasts (FB) [12],
rat proximal tubular epithelial cells (TC) [13], and rat glomerular
endothelial cells (GE) [14] were analyzed by western blot analysis.
The results of immunoblotting with anti-podocyte antibody are
shown in Figure 3. A dominant band at a molecular weight of
70 kD was observed in the membrane-rich fraction from
podocytes (Figure 3.A Lane 1 & 5 ). The 70 Kd band however
was not detected in the membrane fractions from MC, FB, TC, or
GE (Figure 3.A, Lanes 2–4 & 6). Sodium potassium adenosine-
triphosphate (Na+ K+ ATPase) was used as loading control for
membrane protein.
Organ Specificity of Podocyte Antibody In Vivo
To ensure that the sheep anti-podocyte antibody did not bind to
cells in other organs beyond the glomerulus, male Balb-c mice
were injected with anti-podocyte antibody and several organs
harvested 72 hours later (Figure S1). Within the kidney, staining
was detected only in glomeruli, and this was in a podocyte
distribution. In contrast, IgG staining was not detected in the
lungs, liver, muscle or colon (not shown), similar to control mice
injected with normal sheep IgG. As expected, positive staining for
both the anti podocyte antibody and normal sheep IgG used as
control was detected in the spleen. These results are consistent
with non-specific binding or trapping of IgG in the spleen (Figure
S1.C and S1.D). Faint positive staining for sheep anti-mouse
podocyte IgG was also detected in the brain vasculature, but not in
the grey matter or neuronal cells (Figure S1.E and S1.F). No
other vasculature stained positive. Affinity testing of the anti-
podocyte antibody was performed using the original unmodified
antibody, since cleaving of the internal heavy chain disulfide bond
alters the Fc-portion of the antibody [15,16].
Shamporter Uptake by Podocytes
Subcellular protein fractioning, followed by western blot
analysis for sheep IgG, was used to detect anti podocyte antibody
uptake by cultured mouse podocytes. Sheep anti-podocyte
antibody was applied to cultured immortalized mouse podocytes
for 30 minutes on ice, and then unbound IgG was washed away.
Western blot for sheep IgG heavy chain (55 kDa band) showed
that sheep IgG readily bound to the membrane fraction of
podocytes (Figure 3). Following additional 30 minute incubation
at 37uC a strong band for sheep IgG heavy chain was detected in
the cytoplasmic fraction. Alpha-Tubulin (cytoplasmic) and Na+
K+ ATPase (membrane) were used as loading controls. Taken
together, these results show active IgG internalization by
podocytes.
Shamporter Delivery of siRNA Reduces Protein Levels In
Vitro
To ensure that our construct was efficient at transferring siRNA
into podocytes and knocking down target genes, the delivery
system was tested in vitro. Therefore, siRNA specific to the cyclin
dependent kinase inhibitor p57Kip2, cyclin dependent kinase 5
(CDK5) and transient receptor potential channel 6 (TRPC6),
which are constitutively expressed in podocytes [17–19], were
coupled to the shamporter construct and administered to differen-
tiated immortalized mouse podocytes in culture. The results show
that compared to control siRNA, shamporter + p57Kip2 siRNA
reduced p57Kip2 protein to 87% of control after 24 hours, 85%
after 48 hours and 68% of control after 72 hours (Figure 4.A).
Exposing podocytes to Shamporter + CDK5 siRNA reduced CDK5
protein levels to 92% of control after 24 hours, 84% after 48 hours
and 68% after 72 hours compared to control cells exposed to
control siRNA (Figure 4.B). Exposing podocytes to shamporter +
TRPC6 siRNA reduced TRPC6 levels in a dose dependent
manner (Figure 4.C). These results demonstrate that the
shamporter delivery system is effective at getting into podocytes
and specifically decreasing the protein levels of target genes in
cultured podocytes.
Shamporter Delivery of Nephrin and TRPC6 siRNA
Reduces Protein Levels In Vivo
To test delivery of siRNA coupled to shamporter in vivo, siRNA
directed against nephrin or TRPC6 coupled to shamporter was
injected intravenously into uninephrectomized rats (Figure 5).
Western blot and densitometry in Figure 5.A demonstrates
reduced glomerular expression of nephrin in rats injected with
shamporter + nephrin siRNA. Nephrin levels are expressed in ratio
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) used as a
loading control. To further test the reproducibility of shamporter
targeted delivery in vivo, siRNA directed against another podocyte
protein, (TRPC6) was injected. Western blot analysis and
densitometry for TRPC6 on glomerular protein from rats injected
with shamporter coupled to TRPC6 siRNA shows a substantial
reduction in TRPC6 levels compared with rats injected with
shamporter coupled negative control siRNA (Figure 5.B).
Immunohistochemistry on serial kidney sections of rats was used
as another method to demonstrate reduced nephrin levels in
animals injected with shamporter + nephrin siRNA. As shown in
Figure 6, rats injected with shamporter + nephrin siRNA exhibit a
marked decrease in nephrin specific staining, compared with
animals injected with control siRNA. In contrast, there was no
difference in staining for podocin, used as a control. Likewise,
immunofluorescent staining was performed on rats injected with
shamporter + TRPC6 siRNA. There was also a decrease in TRPC6
staining when compared with animals injected with control
siRNA. Interestingly, the staining in the glomerular endothelium
remained. Taken together, these results show that coupling siRNA
to shamporter was effective in reducing nephrin and TRPC6 levels in
vivo in normal rats.
Shamporter Does Not Activate Complement
The potential activation of complement by shamporter was ruled
out by immunofluorescent staining for rat C5b-9 and C3 on tissue
siRNA Delivery to Podocytes
PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9463Figure 2. Affinity of the anti-podocyte antibody. The antibody binds to the apical, basal and the slit diaphragm regions of the podocyte (A). A
small number of immunogold particles were present in the glomerular basement membrane (GBM) and endothelial cells (GEN). The arrows indicate
examples of immunogold particles. Sheep anti mouse podocyte antibody staining was detected only in the glomerulus (B + D arrows) and was
absent in the tubular compartment (D asterix). Control animals injected with normal sheep IgG showed no staining (C + E).
doi:10.1371/journal.pone.0009463.g002
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rats (Figure S2). Rats with Passive Heymann nephritis (PHN),
which are characterized by complement activation, served as
positive controls for the C5b-9 and C3 immunostaining.
Nephrin siRNA Induces Proteinuria
To assess the biological effect of reducing nephrin levels we
measured the urine protein to creatinine ratios (UP:UC) 24 and
72 h after shamporter + nephrin siRNA injection. A significant
increase (ANOVA; p,0.001) in proteinuria was detected in rats
injected with Shamporter + nephrin siRNA at 24 and 72 hours
compared with baseline (Figure 7). There was a slight, but
insignificant increase in proteinuria in control animals at 24 h,
which returned to baseline by 72 h. The transient increase in the
UP:UC ratio at 24 h in the control group can be explained by the
excretion of the normal sheep IgG which was used as a carrier
protein. A significant difference was found between experimental
group and control at 72 h (t-test; p,0.05), UP:UC ratios of both
groups normalized to baseline after 96 h. There were no
differences in BUN measurements 72 hours after treatment with
shamporter + either siRNA (data not shown). These data show that
reducing nephrin levels with a single injection of shamporter+ne-
phrin siRNA induced transient proteinuria.
Nephrin siRNA Induces Podocyte Effacement
In order to determine if Shamporter + nephrin siRNA had any
effects on podocytes at the ultrastructural level, electron
microscopy was performed on biopsies at 72 hours and the results
are shown in Figure 7. Injecting shamporter + control siRNA had
no effect on podocyte morphology (Figure 7.C). In contrast,
administering shamporter + nephrin siRNA caused moderate
effacement of foot processes (Figure 7.B). There were no changes
in the glomerular basement membrane or the glomerular endo-
thelial cells.
To quantitiate these changes, the average podocyte foot process
width (Wp) was measured. The data showed that animals treated
with shamporter + nephrin-siRNA had significantly (p,0.000058)
larger (5666157 nm) foot process width compared to control
animals treated with shamporter + control-siRNA (3656126 nm)
(Figure 6.D).
Discussion
Although several therapeutic agents are currently available to
treat proteinuria caused by podocyte diseases, none are cell-type
specific. As a result, side effects occur due to the delivery of these
agents to organs beyond the intended target. Methods to deliver
therapeutics or experimental drugs can broadly be divided into
methods for systemic delivery and organ or tissue specific. Extensive
work has been undertaken to deliver genes to the kidney, most
recently very successful using podocyte-specific promoter constructs
[20,21,22]. However, hydrodynamic gene delivery via tail vein
requires large volumes and high speed injection that is not readily
achievable in humans. In this manuscript we present a novel
Figure 3. Podocyte antibody specificity and uptakes by podocytes. Western blot analysis with the podocyte antibody on membrane
fractions from cultured immortalized mouse podocytes (P), mouse mesangial cells (MC), mouse fibroblasts (FB), rat proximal tubular epithelial cells
(TC), and rat glomerular endothelial cells (GE), showed a band only in podocytes (A lanes 1 & 5). After 30 minutes at 37uC the cytoplasmic fraction of
podocytes incubated with shamporter, showed a marked increase in detectable sheep IgG (55 kDa). Incubation of cells on 4uC instead significantly
slowed shamporter uptake (B).
doi:10.1371/journal.pone.0009463.g003
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expression by packaging siRNA on an antibody that binds podocyte
membranes and is internalized by endocytosis.
The rationale for the study design was based in part on the
recent observation that podocytes have an active endocytic
machinery [8,9]. Podocytes use a receptor mediated uptake
mechanism to internalize IgG. Akilesh S et al. showed that
podocytes express FcRn, an IgG and albumin transport receptor;
mice deficient for FcRn accumulated IgG in the GBM as they age
[10]. We therefore reasoned that the binding of antibody to the
surface of podocytes would favour internalization of the antibody.
Moreover, if the antibody could be used as a delivery system, one
could then specifically deliver a drug or other substance such as
siRNA to podocytes. The immunogold and immunofluorescent
staining, as well as western blot analysis presented in this
manuscript showed that the antibody we generated did indeed
bind predominantly to podocytes.
The major findings in this study were shamporter efficiently
piggybacks siRNA into podocytes both in vitro and in vivo as evidence
bya decrease inproteinlevelsandimmunostaining.The decreasein
Figure 4. Western blot analyses for p57, CDK5 and TRPC6. In cultured immortalized mouse podocytes transfected with shamporter + siRNA
directed against p57 (A) or CDK5 (B), there was a progressive decrease in protein levels at 48 h and 72 hours. In cultured podocytes transfected with
shamporter + siRNA directed against TRPC6, there was a dose dependent decrease in protein levels for TRPC6 (C). Cells transfected with
nonfunctional control-siRNA served as control. The panels on the right show densitometry performed against loading controls GAPDH or b-Actin.
doi:10.1371/journal.pone.0009463.g004
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process width was consistent with other studies, where a mutation
(and hence function) in one or more amino acids of nephrin were
shown [23,24]. Moreover, administering an antibody specific to
nephrin also induces proteinuria [25]. We were able to confirm the
utility of this delivery system by targeting and decreasing levels of a
second slit diaphragm protein found in the podocyte, transient
receptor potential channel 6 (TRPC6) [19].
Because protamine sulfate is used to induce transient foot
process effacement and proteinuria, a particular concern would be
that the protamine used as a nucleic acid carrier in the shamporter
construct might cause changes in the podocyte itself. The
mechanism by which protamine induces changes in the podocyte
is its cationic charge. However, studies have shown that exposing
protamine to negatively charged nucleic acids in fact changes the
surface charge of protamine from cationic to anionic [26,27].
Given the lack of a cationic charge, it is unlikely that the
protamine itself is inducing changes itself. Furthermore, we
actually looked at foot processes in our studies and showed no
changes in the rats that received shamporter + control siRNA.
The use of antibodies to direct siRNA to specific target cells or
organs has been shown to be a useful approach in other cells [28].
The antibody used in these studies targeted podocytes; however the
antigen(s) recognized by the IgG are unknown. While of potential
interest, defining these antigens is beyond the scope of this
manuscript. Moreover, in its current form, the novelty of effectively
delivering siRNA to the glomerulus is itself a huge undertaking and
the results are not dampened by the antibody specificity. The data
presented here is meant to serve as proof-of-concept that an
antibody system can be effective and fairly specific at targeting
podocytes.Indeed,thisstudyshowsthatitistechnicallyfeasible,and
that others in the future can use this methodology with currently
available podocyte specific antibodies. Identifying the antigen(s) and
improving specificity of delivery are goals of future studies.
The authors note that parietal epithelial cells (PECs) within the
glomerulus have recently been shown to likely serve as progenitors
to podocytes and share some common antigens as do the parietal
podocyte lining parts of Bowman’s basement membrane [29–32].
Indeed, we have a manuscript in press adding to this literature
[33]. These recent studies have dramatically changed previous
notions of ‘‘podocyte specificity’’ using current standard tech-
niques. To this end, the authors believe that no antibody is
therefore completely podocyte specific as long as PECs and
podocyte gene expression overlaps.
This observation therefore also opens the possibility that PECs
serving as progenitors may also be targeted by our delivery system.
Thus, care needs to be taken when designing the targets with this
system, so as not to interfere with the natural repair system these
progenitors may provide in replacing damaged or lost podocytes.
Likewise, while we did test for binding of the antibody in several
organs asdiscussed inthe manuscript, there is the possibility that the
unidentified antigen(s) may be present within other organs and this
could lead toofftargeteffects.This istrue ofmanyantibodydelivery
systems.
Figure 5. Western blot analysis for Nephrin and TRPC6 in rats injected with shamporter and siRNA. Rats were injected via tail vein with
shamporter + control siRNA or shamporter + nephrin siRNA or shamporter + TRPC6 siRNA. Compared with control siRNA injected rats, there was a
significant decrease in nephrin protein levels in the rats injected with nephrin siRNA (A). Likewise, there was a significant decrease in TRPC6 protein
levels in the rats injected with TRPC6 siRNA (B). Staining for GAPDH or beta actin was used as a protein loading control, and the podocyte specific
protein podocin or nephrin were used to ensure that the same amount of podocyte protein was loaded. Densitometry and of the results are shown in
the graph. Ratios were compared using t-test (p,0.05); ratios are expressed as median 6 min and max values.
doi:10.1371/journal.pone.0009463.g005
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targeted genes, we believe that repeated injections of shamporter
may enable longer-term knockdown and studies are ongoing to
test this.
One might ask why the delivery of the modified antibody does
not induce disease. Studies have shown that a monovalent
antibody is not complement activating, which is one of the
reasons for the lack of host response and disease induction [16].
Our results were consistent with this observation. Furthermore, in
a recently published collaborative study utilizing this antibody, it
was shown DAF-deficient T cells are required for induction of
disease with the intact version of this antibody [34].
While gene knock-down in animals are typically performed at
the genomic level by introducing mutations. These mutations lead
to either a permanent or conditional mutant phenotype. In the
conditional variant, the phenotype will occur only in a temporary
or spatial manner, for example only during certain stages of
development or only in the kidney [35,36]. While these gene
knock-downs are valuable and helpful in our understanding of the
function of specific genes, there are problems associated with these
models. Mutations in essential genes can result in lethality or a
renal phenotype that is non-functioning. Additionally, while
inducible systems are being developed [37], traditionally muta-
tions can not be switched on and off and therefore the influence of
specific genes on the progression of ongoing disease can only be
studied within limits. Likewise there is substantial cost in
developing these models. A study by the NIH found that
generating a transgenic mouse typically takes about one year
and costs between one and two hundred thousand dollars [38].
In conclusion, we show that use of a modified antibody to
deliver siRNA to podocytes is an effective methodology in vivo,
without systemic effects.
Methods
Immortalized Mouse Podocyte Culture
Immortalized mouse podocytes in culture were utilized as both
the antigen to produce an antibody and to test the utility of our
Figure 6. Immunohistochemistry for nephrin, podocin and TRPC6. Animals injected with shamporter + control siRNA show a strong linear
staining signal for nephrin and podocin, as well as glomerular staining for TRPC6. In animals injected with shamporter + nephrin or TRPC6 specific
siRNA, the staining signal was significantly reduced, while the signal for podocin remained unchanged. When nephrin, podocin, or TRPC6 antibodies
were omitted, no staining was detected.
doi:10.1371/journal.pone.0009463.g006
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from H-2Kb-tsA58 transgenic mice kidneys (ImmortoMouseH; The
Jackson Laboratory, Bar Harbor, ME, USA) as recently described
[39,40] ImmortoMouseH harbors a temperature-sensitive SV40
large T cell antigen (tsA58 Tag) under the control of an interferon-c
inducible H-2Kb promoter. Under growth permissive conditions
(33uC with 50 units/ml mouse INF-c) podocytes proliferate and
under growth restrictive conditions (37uC in the absence of mouse
INF-c) podocytes stop proliferating and differentiate, displaying
many features of podocytes in vivo. Podocytes were grown in
standard RPMI 1640 medium that contained 10% FBS (Fetal-
plex
TM, Gemini Bio-Products, West Sacramento, CA, USA),
penicillin (100 U/ml), streptomycin (100 mg/ml), sodium pyruvate
(1 mmol/L; (all Irvine Scientific, Santa Ana, CA, USA), HEPES
buffer (10 mmol/L; Sigma Chemical Co., St. Louis, MO, USA),
and sodium bicarbonate (0.075%; Sigma Chemical Co.). Podocytes
were characterized as previously described [41]. Fully differentiated
podocytes between 12–18 passages were utilized for our studies.
Generation of a Podocyte Specific Antibody
In order to devise a novel podocyte specific siRNA delivery
system, we developed an antibody that would specifically bind to
Figure 7. Proteinuria and Podocyte abnormalities induced in nephrin siRNA injected rats. Urinary protein (UP) to urinary creatinine (UC)
ratio (mg/mg) was used to assess renal function. UP:UC ratio was increased significantly in rats injected with shamporter + nephrin siRNA after 24 and
72 h compared to baseline (ANOVA; p,0.001). 72 h after injection, shamporter + nephrin siRNA injected rats exhibited a significantly higher UP:UC
ratio then animals from the control group (t-test; p,0.005). No significant differences in UP:UC ratio was found between control animals at 72 h and
baseline (A) No difference was found in BUN in either group (data not shown). There were no abnormalities in podocytes in control rats injected with
shamporter + control siRNA (C). Arrows indicate normal slit diaphragms. In rats injected with shamporter + nephrin siRNA, there was loss of normal slit
diaphragm architecture which included crowding of the slit diaphragms and reduced space between adjacent foot processes (B arrows).
Quantification of foot process width showed a significant increase in rats injected with shamporter + nephrin siRNA compared with rats injected with
shamporter + control siRNA (D).
doi:10.1371/journal.pone.0009463.g007
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cytes (3–5610
6 cells) were combined with complete Freund’s
adjuvant (2 ml) for the first immunization of a sheep. Incomplete
Freund’s adjuvant was used for subsequent immunizations and
administered to the sheep subcutaneously at multiple sites.
Following more than 10 cycles of immunizations, the sheep
underwent plasmapharesis at peak antibody titer (10 days
following immunization). IgG was then isolated from the plasma
using caprylic acid followed by ammonium persulfate precipitation
[42]. Isolated IgG was dialyzed against PBS and sterile filtered. We
and others have previously reported that the injection of a similar
anti-podocyte antibody into mice induces experimental glomerular
disease [43,44]. Thus in order to take full advantage of the affinity
of the antibody for the podocyte, while at the same time
preventing the antibody from inducing disease, the anti mouse
podocyte was modified extensively as described below.
Characterization of a Podocyte Specific Antibody
Western blot analysis was performed on membrane preparations
extracted from fully differentiated immortalized mouse podocytes
[39,40] mouse mesangial cells [11], mouse fibroblasts [12], rat
proximal tubular epithelial cells [13], and rat glomerular endothelial
cells [14], as described below. Protein concentrations were
determinedusingtheBCAproteinassay(Pierce,Rockford,IL,USA).
Uptake of Podocyte Specific Antibody by Podocytes
Fully differentiated immortalized mouse podocytes were
incubated with 2 mg/ml podocyte specific IgG on ice for 30
minutes to allow binding. Another group of podocytes were
incubated with podocyte specific antibody as described, then
subjected to additional 30 minute incubation at 37uC to allow
internalization of podocyte specific IgG. Cells were lysed in
10 mM Tris buffer (pH 7.5) containing 300 mM sucrose, 1 mM
EDTA (all from Sigma-Aldrich, St. Louis, MO), protease
inhibitors (Roche, Indianapolis, IN), 50 mM NaF (Sigma-Aldrich),
1 mM Na-orthovanadate (Sigma-Aldrich). The cell homogenate
was centrifuged for 2 min at 8006g to clear the lysates from
cellular debris and unlysed cells. The supernatant was further
centrifuged for 2 min at 2,0006g. The pellet contained the
nuclear fraction. The supernatant was further centrifuged for
20 min at 10,0006g to separate cellular organelles from cytosolic
proteins. The supernatant was centrifuged for 1 h at 100,0006g
resulting in the cytosolic fraction (supernatant). The pellet was
washed and centrifuged an additional 1 h at 100,0006g resulting
in the membrane fraction (pellet). Membrane and cytosolic
subcellular fractions from both groups were analyzed by western
blot analysis for sheep IgG heavy chain. Alpha/beta tubulin
cytoplasmic) and sodium potassium adenosine-triphosphatase
(membrane) were used as loading controls for each fraction.
Modification of Sheep Anti-Mouse Podocyte Antibody
Purified IgG (10 mg) was selectively cleaved at the internal
heavy-chain disulfide bond with 2-MEA at a concentration of
50 mM (2-mercaptoethylamine-HCl; Pierce, Rockford, IL, USA)
(Figure 1, step 1). 2-MEA was then removed using a desalting
column. Cleaving the polyvalent antibody with 2-MEA produced
two monovalent antibody fragments, thereby destroying the ability
of the antibody to activate complement [15,16], while leaving the
antigen recognition sites intact.
Following IgG cleavage, the sulfohydryl group was utilized to
link a defined number of Neutravidin molecules (n=1) to each
monovalent IgG. NeutrAvidinTM protein was conjugated to the
monovalent IgG using EZ-Link kit per the manufacturer’s
instructions (EZ-LinkH Maleimide Activated NeutraAvidinTM
Protein; Pierce, Rockford, IL, USA). (Figure 1, step 2)
Next, we added protamine, a universal adaptor for siRNA and
other nucleic acids onto the monovalent antibody [26]. Protamine
is a polycationic nuclear protein (MW ,4000 Da) that binds DNA
during the haplophase in the absence of histones [45]. Protamine
stabilizes nucleic acids and also prevents siRNA from enzymatic
degradation, thereby increasing the siRNA half life [46].
Protamine sulphate is an FDA approved compound and its safety
is well documented, making it suitable even for applications in
human therapy [47]. Protamine sulphate (Salmine P4020, Sigma,
St. Louis, MO, USA) was biotinylated via it’s N-terminal amino
group using EZ-LinkH Sulfo-NHS-Biotinylation Kit per the
manufacturer’s instructions (Pierce, Rockford, IL, USA)
(Figure 1, step 3). The modified antibody containing the
Neutravidin site and the biotinylated protamine were mixed in a
ratio of 1:1.2 and incubated for 60 minutes on a rotor at 4uC. To
remove unbound protamine and conjugation buffer, the antibody-
protamine complex was dialyzed overnight against phosphate
buffered saline pH 8.3 at 4uC in a 10,000 molecular weight cut-off
Slide-A-LyzerH cassette (Pierce, Rockford, IL, USA) (Figure 1,
step 3). Because protamine is positively charged, it attracts the
negative charge of siRNA and allows transport of siRNA directly
to the podocyte (Figure 1, steps 4 & 5). We called this novel
podocyte specific siRNA delivery system shamporter (sheep anti
mouse podocyte transporter).
Design and Synthesis of siRNA
In order to test the feasibility of the delivery system, we
employed siRNA to genes that are constitutively expressed in
podocytes. Accordingly, the following commercial siRNAs were
utilized: (i) siRNA directed against the cyclin dependent kinase
inhibitor p57Kip2 (M-062494, Dharmacon Inc., Chicago, IL,
USA), (ii) siRNA directed against glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and (iii) siRNA directed against cyclin
dependent kinase five (CDK5) 4390849 & 60726 Applied
Biosystems, Austin, TX, USA) and (iv) Silencer Negative Control
#1 siRNA (AM4635 Applied Biosystems, Austin, TX, USA) was
utilized as a negative control. (v) Additionally, siRNA directed
against nephrin (Npsh1) and TRPC6 were designed using the
RiDDLE database [48] and synthesized using SilencerTM siRNA
Cocktail Kit, (Ambion, Applied Biosystems, Austin, TX, USA)
according to the manufacturer’s protocol.
Shamporter In Vivo
To ensure that there was no non-specific binding of the anti-
podocyte antibody in organs outside the kidney, male Balb/c mice
(n=4, bodyweight 22–35 g) were injected with a single dose
(15 mg/20 g BW) of mouse anti-podocyte antibody into the tail
vein. Control animals (n=4) received normal sheep IgG (15 mg/
20 g BW). After 72 hours, mice were sacrificed and biopsies were
taken from kidney, heart, brain, lung, spleen, liver, colon and
muscle, snap frozen and embedded in OCT for immunostaining
for sheep IgG. Immunofluorescent staining for sheep IgG was
performed on 4 mm frozen sections from each organ to determine
if podocyte antibody deposited in these organs. Sections were fixed
in methanol for 30 minutes at 220uC, washed in phosphate
buffered saline, and incubated with fluorescein conjugated rabbit
anti-sheep IgG antibody (Abcam, Cambridge, MA, USA).
Delivering siRNA to Podocytes In Vivo
Nephrin has been well studied and mutations or alterations of
the subcellular level of nephrin lead to proteinuria [16,21]. Thus,
in order to test the delivery of shamporter to podocytes in vivo, siRNA
siRNA Delivery to Podocytes
PLoS ONE | www.plosone.org 10 March 2010 | Volume 5 | Issue 3 | e9463directed against nephrin was linked to shamporter and used as
follows. Six normal adult male Sprague-Dawley rats (Charles
River Labs, Boston, MA, USA) (144 g610) were uninephrecto-
mized to reduce the glomeruli number, then injected intravenously
with 0.3 mmol of modified anti podocyte antibody (shamporter)i n
combination with 2 mmol siRNA directed against nephrin.
Control animals received 0.3 mmol shamporter in combination with
2 mmol non-functional control siRNA. Normal sheep IgG in
500 ml sterile PBS was used as vehicle for shamporter and siRNA to
control non-specific IgG binding.
To silence TRPC6 expression in podocytes in vivo, we injected
shamporter + TRPC6 siRNA in four male Sprague-Dawley rats
(150–190 g). Again, animals were uninephrectomized to reduce
the glomeruli number. Nephrectomized kidneys served as normal
control kidneys. After five days each rat was injected intravenously
with 2 mg Shamporter + 2 mg normal sheep IgG + 50 nM TRPC6
siRNA (2 rats) or 50 nM negative control siRNA (2 rats). The
concentration of siRNA was calculated on an estimated blood
volume of 10 ml. Experimental and control animals were
sacrificed after 48 hours, kidney biopsies were harvested and
processed for further analysis. Glomerular preparations were
performed, as described before [49], to determine levels of TPRC6
in podocytes by western blot analysis.
All interventions were performed under a general anesthetic
composed of 50% ketamine, 25% xylazine, 15% azepromazine (all
Phoenix Pharmaceuticals, St. Joseph, MO, USA) and 10%
Ringer’s solution (Baxter Healthcare, Deerfield, IL) at a dose of
100 ml per 100 g body weight. Animals were housed with free
access to food and water. Experimental and control animals were
sacrificed after 72 hours, and kidney biopsies were obtained, fixed
and immunostained as described below.
Measuring Renal Function
In order to assess renal function, urine was collected by placing
animals in metabolic cages for 12 hours, during which time water
was supplied without restriction. Urine was collected before
shamporter injection (baseline), and 24, 48, 72, 96 hours, and 7 days
after shamporter injection. Total protein excretion was determined
by the sulfosalicylic acid turbidity method as previously described
[51]. Urine creatinine excretion was measured using a commer-
cially available colorimetric microplate assay based on the Jaffe
reaction (Colorimetric Creatinine Assay Kit, CR01, Oxford
Biomedical Research, MI, USA) [52].
Immunohistochemical Staining
To ensure that the levels of nephrin were reduced, indirect
immunoperoxidase staining was performed for nephrin and
podocin on serial sections from formalin fixed paraffin embedded
kidney tissue as previously described [50,53].
Briefly, paraffin was removed with Histoclear (National
Diagnostics, Atlanta, GA, USA) and sections were re-hydrated
in ethanol. Antigen retrieval was performed by boiling sections in
1 mM ethylenediaminetetraacetic acid (EDTA) buffer pH 6.0.
Endogenous peroxides activity was quenched with 3% hydrogen
peroxide and non-specific protein binding was blocked with
Background Buster (Accurate Chemical&Scientific Corporation,
Westbury, NY, USA). Endogenous biotin activity was quenched
with Avidin/biotin blocking kit (Vector Laboratories, Burlingame,
CA, USA). After blocking sections were incubated with either
polyclonal nephrin or podocin antibodies (antibodies listed below)
overnight at 4uC, unbound antibody was removed by washing in
PBS and biotin-labelled goat antibody directed against guinea pig
or rabbit IgG was applied for 1 hour at room temperature.
R.T.U. Vectastatin kit was applied (Vector Laboratories) and
staining was visualized by precipitation of Diaminobenzidine
(DAB) (Sigma Aldrich) for nephrin or Vector SG substrate kit as
per manufacturer’s instructions for podocin. The primary
antibodies were omitted as negative controls.
Immunofluorescent Staining
Frozen 4 mm sections were fixed in 100% methanol and
incubated with rabbit TRPC6 antibody followed by FITC labelled
mouse anti-rabbit IgG, or biotin labelled monoclonal anti rat c5b-
9 followed by streptavidin-fluorescein or FITC labelled goat
polyclonal to Rat C3.
Western Blot Analysis
Western blot analysis was also performed as described previously
to further quantitate any decrease in target gene protein levels [48].
Briefly, 20 mg protein extracts in Laemmli buffer containing 5% 2-
Mercaptoethanol were separated by sodium dodecyl sulfate–
polyacrylamide (SDS) gel electrophoresis and transferred to
polyvinylidene difluoride membrane. After blocking non-specific
binding with 5% non fat dry milk or 5% bovine serum albumin
(Sigma Chemicals, St. Louis, MO, USA), membranes were
incubated overnight at 4uC with primary antibodies (see below).
Secondary anti-rabbit IgG horseradish peroxidase antibody (GE
Healthcare, Piscataway, NJ, USA) was applied for 1 hour at room
temperature followed by enhanced chemoluminescence (ECL)
western blotting system (GE Healthcare, Piscataway, NJ, USA).
Antibodies
The following antibodies were utilized: Guinea pig polyclonal to
Nephrin, RDI-PROGPN2 (Fitzgerald, Concord, MA, USA); Anti
human Podocin IgG, PODO11-A (Alpha Diagnostic, San Antonio,
TX, USA); Rabbit polyclonal to TRPC6, ACC-017 (Alomone labs,
Jerusalem, Israel); Rabbit polyclonal to TRPC6, ab47679 (Abcam,
Cambridge, MA, USA); FITC labelled Goat polyclonal to Rat C3
(MP Biochemicals, Solon, Ohio, USA); Biotin labelled monoclonal
anti rat c5b-9 (SantaCruz Biotechnology, Inc., Santa Cruz, CA.
USA); Streptavidin-fluorescein & Donkey ECL anti rabbit IgG
(HRP), NA934 (GE Healthcare, Piscataway, NJ, USA); Rabbit
polyclonal anti-guinea pig IgG H&L (HRP), ab6771 (abcam,
Cambridge, MA, USA); FITC labelled rabbit polyclonal anti sheep
IgG H&L, ab6743 (abcam, Cambridge, MA, USA); FITC labelled
mouse anti-rabbit IgG (Jackson, West Grove, PA, USA); Biotin
labelled goat polyclonal anti-guinea pig IgG, BA-7000 and biotin
labelled goat polyclonal anti rabbit IgG (both Vector Laboratories,
Burlingame, CA, USA).
Morphometric Evaluation
To determine the average foot process width, 20 electron
microscopy images from 4 animals of each group, at 71006
magnification were examined. On each image, the curved total
length of the basement membrane (BML) was measured using
Image J [54]. Counting the number slit diaphragms; the average
foot process width (Wp) was calculated using the formula below
[55].
Wp~p=4|
X
BML
.X
Slits
Statistical Analysis
Results are expressed as mean 6 standard error of the mean.
Paired t-test was used in the densitometry analysis. Statistical
significance was defined as p,0.05; test was performed using
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calculate intra group differences of the in vivo experiment [56].
Protein/creatinine ratios are expressed as median 6 max and min.
Student t-test was used to compare protein/creatinine ratios of
treated to untreated rats, statistical significance was defined as
p,0.05.
Animal Experiments
Animals used in this study were housed in the University of
Washington animal facility according to standardized specific
pathogen-free conditions. Experimental procedures involving
animals were reviewed and approved by the Animal Care
Committee of the University of Washington. Researchers handling
animals were trained and certified according the guidelines of the
American Association for Laboratory Animals (ALAAS).
Supporting Information
Figure S1 Immunofluorescent staining of anti mouse podocyte antibody in
different organs following tail vein injection. (A) Sheep anti mouse
podocyte antibody staining was detected only in the glomerulus,
and this was in a podocyte distribution (B). Staining was absent in
the control animals injected with normal sheep IgG. (C) In the
spleen, there was staining for both anti-mouse podocyte antibody
and normal sheep IgG injected control (D) consistent with IgG
trapping. (E) Antibody staining was detected in brain vasculature.
(F) Staining for normal sheep IgG was absent in the brain.
Found at: doi:10.1371/journal.pone.0009463.s001 (1.47 MB TIF)
Figure S2 Complement staining in shamporter injected animals. Immune
fluorescence staining for showing absence of complement
activation in shamporter injected rats. Animals injected with
shamporter + control siRNA or shamporter +nephrin siRNA do
not show positive signals for complement factors C5b-9 (B+C) or
C3 (E+F). Rat with Passive Heymann Nephritis was used as a
positive control shows typical staining for C5b-9 and C3 (A+C).
Found at: doi:10.1371/journal.pone.0009463.s002 (1.28 MB TIF)
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